Super piggyBac® Licensing

High-Performance, Non-Viral Gene Integration with Clear IP Ownership

Overview

Super piggyBac is a proprietary, non‑viral transposase platform with clear and consolidated IP ownership. Following Demeetra’s acquisition of Hera BioLabs, Super piggyBac is exclusively licensed by Demeetra for research, development, and commercial use.

Demeetra provides direct, predictable licensing pathways for Super piggyBac, supporting use from exploratory research through product development and commercialization.

License Access Options

Demeetra offers flexible Super piggyBac licensing models aligned to how organizations adopt and deploy the technology, from initial evaluation to enterprise-wide use.

Evaluation

  • One time piggyBac starter kit
  • Includes piggyBac transposase mRNA and two transposon constructs, designed for initial feasibility testing and internal benchmarking.
  • $5,000 one-time

Cell & Gene Therapy R&D

  • Licensed use for advanced cell and gene therapy research workflows.
  • Unlimited internal generation and use of derivative materials.
  • Contact us for pricing structures

Screening & Research Models

  • Ideal for large-scale screening, model generation, and platform deployment.
  • Unlimited internal generation and use of derivative materials.
  • $50k/year or $5,000/month

Commercial License

  • Required to sell research tools, models, or diagnostic products developed using Super piggyBac.
  • Unlimited internal generation and use of derivative materials.
  • $100k/year or $10,000/month
All license models come with up to 40x vials of premium piggyBac transposase mRNA per year

Why License Super piggyBac Through Demeetra

Clear Freedom to Operate from the Original IP Owner

Licensing Super piggyBac directly from Demeetra removes uncertainty around derivative use, downstream applications, and commercialization. Super piggyBac is not open‑source. Demeetra holds exclusive rights to Super piggyBac and its related technologies, including hyperactive derivatives such as hyPBase.

Working with the original IP holder provides a clear, supported path from internal research through commercial deployment, without ambiguity around redistribution, modification, or field‑of‑use expansion.

Platform‑Level Performance Without IP Tradeoffs

Super piggyBac has demonstrated multi‑fold performance gains over other transposase systems across diverse mammalian cell types. Its performance is comparable to hyperactive variants such as hyPBase, which themselves require access to Demeetra IP, making Super piggyBac the preferred platform for teams seeking both high performance and a clean IP position.

This combination positions Super piggyBac as a gold‑standard, non‑viral integration platform for cell and gene therapy R&D.

Non‑Viral Integration for Practical Scale‑Up

Super piggyBac enables efficient, stable gene integration without viral vectors, reducing operational complexity and cost while accelerating iteration. This non‑viral approach supports workflows where viral delivery is impractical, undesirable, or cost‑prohibitive—particularly in discovery, cell line development, and translational research environments.

Trusted by Industry Leaders

Demeetra’s Super piggyBac platform is licensed by 9 of the world’s top 20 pharmaceutical companies by revenue, along with more than 50 leading CDMOs, CROs, and next-generation cell and gene therapy innovators.

Ready to Advance Your Programs?

Super piggyBac combines non-viral delivery, high-efficiency integration, and elevated copy number with clear, origin-linked IP. Whether supporting advanced cell and gene therapy research or powering large-scale screening and commercial research tools, Demeetra provides a clear, supported path to confident adoption.

Discuss Licensing Options
Order an Evaluation Kit